Since 2008, because of safety concerns, the FDA has mandated long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes.1 Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table) have led to new recommendations.2-4
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes. JAMA. 2019;321(17):1720–1721. doi:10.1001/jama.2019.2702
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: